Notably, toripalimab was administered empirically, as immune-related biomarkers such as programmed death ligand-1 (PD-L1) expression, tumor mutational burden (TMB), and microsatellite instability (MSI)/mismatch-repair (MMR) status were not available for the patient. This evidence concerns the gene CD274 and neoplasm.